Sudan Loganathan
Stock Analyst at Stephens & Co.
(1.74)
# 2,348
Out of 4,479 analysts
9
Total ratings
33.33%
Success rate
-3.63%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNSE Sensei Biotherapeutics | Reiterates: Overweight | $5 | $0.60 | +740.34% | 2 | May 24, 2024 | |
| EXEL Exelixis | Initiates: Equal-Weight | $23 | $22.25 | +3.37% | 1 | May 14, 2024 | |
| ELEV Elevation Oncology | Initiates: Overweight | $8 | $2.86 | +179.72% | 1 | May 14, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Overweight | $20 | $20.91 | -4.35% | 1 | May 14, 2024 | |
| INO Inovio Pharmaceuticals | Initiates: Overweight | $20 | $8.61 | +132.29% | 1 | May 14, 2024 | |
| BPMC Blueprint Medicines | Initiates: Overweight | $140 | $109.18 | +28.23% | 1 | May 14, 2024 | |
| ATNM Actinium Pharmaceuticals | Initiates: Overweight | $25 | $7.20 | +247.22% | 1 | May 14, 2024 | |
| DCTH Delcath Systems | Initiates: Overweight | $25 | $8.26 | +202.66% | 1 | May 14, 2024 |
Sensei Biotherapeutics
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.60
Upside: +740.34%
Exelixis
May 14, 2024
Initiates: Equal-Weight
Price Target: $23
Current: $22.25
Upside: +3.37%
Elevation Oncology
May 14, 2024
Initiates: Overweight
Price Target: $8
Current: $2.86
Upside: +179.72%
Nurix Therapeutics
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $20.91
Upside: -4.35%
Inovio Pharmaceuticals
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $8.61
Upside: +132.29%
Blueprint Medicines
May 14, 2024
Initiates: Overweight
Price Target: $140
Current: $109.18
Upside: +28.23%
Actinium Pharmaceuticals
May 14, 2024
Initiates: Overweight
Price Target: $25
Current: $7.20
Upside: +247.22%
Delcath Systems
May 14, 2024
Initiates: Overweight
Price Target: $25
Current: $8.26
Upside: +202.66%